Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. More Details
High growth potential with mediocre balance sheet.
Share Price & News
How has Cassiopea's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SKIN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SKIN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
7 Day Return
1 Year Return
Return vs Industry: SKIN exceeded the Swiss Pharmaceuticals industry which returned -1.1% over the past year.
Return vs Market: SKIN exceeded the Swiss Market which returned 21% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cassiopea's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWhen Will Cassiopea S.p.A. (VTX:SKIN) Breakeven?
3 months ago | Simply Wall StCassiopea (VTX:SKIN) Is In A Good Position To Deliver On Growth Plans
5 months ago | Simply Wall StCassiopea S.p.A. (VTX:SKIN) Is Expected To Breakeven In The Near Future
Is Cassiopea undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SKIN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SKIN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SKIN is unprofitable, so we can't compare its PE Ratio to the XE Pharmaceuticals industry average.
PE vs Market: SKIN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SKIN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SKIN is overvalued based on its PB Ratio (30.3x) compared to the CH Pharmaceuticals industry average (3.1x).
How is Cassiopea forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SKIN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).
Earnings vs Market: SKIN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SKIN's is expected to become profitable in the next 3 years.
Revenue vs Market: SKIN's revenue (45.3% per year) is forecast to grow faster than the Swiss market (4.5% per year).
High Growth Revenue: SKIN's revenue (45.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SKIN's Return on Equity is forecast to be high in 3 years time
How has Cassiopea performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SKIN is currently unprofitable.
Growing Profit Margin: SKIN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SKIN is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare SKIN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SKIN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.6%).
Return on Equity
High ROE: SKIN has a negative Return on Equity (-78.82%), as it is currently unprofitable.
How is Cassiopea's financial position?
Financial Position Analysis
Short Term Liabilities: SKIN's short term assets (€5.8M) exceed its short term liabilities (€2.9M).
Long Term Liabilities: SKIN's short term assets (€5.8M) exceed its long term liabilities (€66.0K).
Debt to Equity History and Analysis
Debt Level: SKIN's debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if SKIN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SKIN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SKIN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.4% each year
What is Cassiopea current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SKIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SKIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SKIN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SKIN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SKIN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Diana Harbort (54 yo)
Ms. Diana Harbort serves as the Chief Executive Officer of Cassiopea S.p.A. since 2015 and has been its Executive Director since May 2015. Ms. Harbort served as the Head of Corporate Development at Medicis...
CEO Compensation Analysis
Compensation vs Market: Diana's total compensation ($USD573.96K) is below average for companies of similar size in the Swiss market ($USD967.32K).
Compensation vs Earnings: Diana's compensation has increased whilst the company is unprofitable.
Experienced Management: SKIN's management team is considered experienced (4.3 years average tenure).
Experienced Board: SKIN's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.5%.
Cassiopea S.p.A.'s company bio, employee growth, exchange listings and data sources
- Name: Cassiopea S.p.A.
- Ticker: SKIN
- Exchange: SWX
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF522.450m
- Shares outstanding: 10.75m
- Website: https://www.cassiopea.com
Number of Employees
- Cassiopea S.p.A.
- Via Cristoforo Colombo, 1
Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has complete...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/09 17:12|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.